A 56 year old female presented with breast carcinoma and she was prescribed herceptin (trastuzumab). Which of the following statements regarding this drug is true ?
**Core Concept:**
Herceptin (trastuzumab) is a monoclonal antibody drug that targets the human epidermal growth factor receptor 2 (HER2) protein. It is used in the treatment of HER2-positive breast cancer, targeting the overactive HER2 pathway, which contributes to cancer cell growth and proliferation.
**Why the Correct Answer is Right:**
Trastuzumab belongs to a class of drugs called monoclonal antibodies, which are engineered to mimic the immune system's ability to fight off infections and tumors. In the case of trastuzumab, it is designed to bind to the HER2 protein expressed on the surface of HER2-positive cancer cells. By binding to this receptor, trastuzumab prevents the HER2 protein from sending signals that promote cell division and growth. This helps to slow down or stop the growth of cancer cells, making trastuzumab a targeted therapy for HER2-positive breast cancer.
**Why Each Wrong Option is Incorrect:**
A. This statement is incorrect because trastuzumab is a monoclonal antibody targeting HER2, not an inhibitor of tyrosine kinase enzymes like lapatinib.
B. This statement is wrong because trastuzumab does not primarily target estrogen or progesterone receptors, which are involved in the hormonal therapy of breast cancer. Trastuzumab targets HER2.
C. This statement is incorrect as trastuzumab is a monoclonal antibody targeting HER2, not an immune checkpoint inhibitor like pembrolizumab or nivolumab.
D. This statement is not accurate because trastuzumab targets HER2, not the epidermal growth factor receptor (EGFR) which is another type of receptor tyrosine kinase involved in cancer growth and progression.
**Clinical Pearl:**
Trastuzumab is a crucial component of HER2-positive breast cancer treatment regimens due to its ability to target and inhibit HER2 signaling. Combining trastuzumab with chemotherapy and endocrine therapy can improve survival rates and reduce the risk of cancer recurrence. Always verify HER2 status in breast cancer patients before prescribing trastuzumab, as it only benefits HER2-positive cases.